{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["74(7)"],"submitter":["Skowronski DM"],"funding":["Roche, Hologic, and Siemens","Public Health Agency of Canada","GlaxoSmithKline","Symvivo","Pfizer","BC Children’s Hospital Foundation","Michael Smith Foundation for Health Research","Sanofi-Pasteur","Seqirus","Canadian Institutes of Health Research","Merck","Canadian Child Health Clinician Scientist Program,"],"pubmed_abstract":["Background
Randomized-controlled trials of messenger RNA (mRNA) vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) included relatively few elderly participants. We assess single-dose mRNA vaccine effectiveness (VE) in adults ≥ 70 years old in British Columbia, Canada, where second doses were deferred by up to 16 weeks and where a spring 2021 wave uniquely included codominant circulation of Alpha (B.1.1.7) and Gamma (P.1) variants of concern (VOC).Methods
Analyses included community-dwelling adults ≥ 70 years old with specimen collection between 4 April (epidemiological week 14) and 1 May (week 17) 2021. Adjusted VE was estimated by test-negative design. Cases were reverse-transcription polymerase chain reaction (RT-PCR) test-positive for"],"journal":["Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"],"pagination":["1158-1165"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8406884"],"repository":["biostudies-literature"],"pubmed_title":["Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada."],"pmcid":["PMC8406884"],"pubmed_authors":["Zou M","Patrick DM","Henry B","El Adam S","Skowronski DM","Jassem AN","Krajden M","Sadarangani M","Hoang LMN","Prystajecky N","Setayeshgar S","Naus M","Tyson JR","Sbihi H","Galanis E"],"additional_accession":[]},"is_claimable":false,"name":"Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada.","description":"Background
Randomized-controlled trials of messenger RNA (mRNA) vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) included relatively few elderly participants. We assess single-dose mRNA vaccine effectiveness (VE) in adults ≥ 70 years old in British Columbia, Canada, where second doses were deferred by up to 16 weeks and where a spring 2021 wave uniquely included codominant circulation of Alpha (B.1.1.7) and Gamma (P.1) variants of concern (VOC).Methods
Analyses included community-dwelling adults ≥ 70 years old with specimen collection between 4 April (epidemiological week 14) and 1 May (week 17) 2021. Adjusted VE was estimated by test-negative design. Cases were reverse-transcription polymerase chain reaction (RT-PCR) test-positive for","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2026-05-08T22:53:27.552Z","creation":"2022-02-11T09:58:26.215Z"},"accession":"S-EPMC8406884","cross_references":{"pubmed":["34244723"],"doi":["10.1093/cid/ciab616"]}}